Ancora Advisors’s Cullinan Oncology CGEM Stock Holding History

Ancora Advisors’s Portfolio CGEM Stock Details CGEM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-200	Closed	-$2.15K	–	1785
2023 Q2	$2.15K	Buy	+200	New	+$2.12K	﹤0.01%	1474

Other funds holding CGEM

MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return

CHI Advisors New York $252M AUM 56.99% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

AIG

American International Group New York $609M AUM 23.67% 1-Year Est. Return

Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Ancora Advisors's CGEM Position: Q3 2023 in Review

Ancora Advisors sold out of Cullinan Oncology (CGEM) in Q3 2023, closing a stake of 200 shares — an estimated $2.15K sold.

Ancora Advisors first reported a position in CGEM in Q2 2023 and held it in 1 quarter. The position peaked at $2.15K in Q2 2023. 106 funds tracked by Wall St. Rank hold CGEM as of Q3 2023.

Ancora Advisors reported no remaining Cullinan Oncology position as of Q3 2023 after selling out during the quarter.
Ancora Advisors sold 200 Cullinan Oncology shares in Q3 2023, an estimated $2.15K.
Ancora Advisors first reported a position in Cullinan Oncology in Q2 2023 and held it in 1 quarter.
Ancora Advisors's Cullinan Oncology position peaked at $2.15K in Q2 2023.
106 funds tracked by Wall St. Rank held Cullinan Oncology as of Q3 2023.

Based on Ancora Advisors's 13F filing for Q3 2023, filed 14 Nov 2023.